▶ 調査レポート

世界のジストロフィー表皮水疱症治療市場2020年-2030年:治療タイプ別(抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他)、疾患別、流通チャンネル別

• 英文タイトル:Dystrophic Epidermolysis Bullosa Treatment Market (Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, and Others; Disease Type: Dominant Dystrophic Epidermolysis Bullosa [DDEB] and Recessive Dystrophic Epidermolysis Bullosa [RDEB]; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Transparency Market Researchが調査・発行した産業分析レポートです。世界のジストロフィー表皮水疱症治療市場2020年-2030年:治療タイプ別(抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他)、疾患別、流通チャンネル別 / Dystrophic Epidermolysis Bullosa Treatment Market (Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, and Others; Disease Type: Dominant Dystrophic Epidermolysis Bullosa [DDEB] and Recessive Dystrophic Epidermolysis Bullosa [RDEB]; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030 / MRC21A34資料のイメージです。• レポートコード:MRC21A34
• 出版社/出版日:Transparency Market Research / 2020年11月26日
• レポート形態:英文、PDF、168ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥631,655 (USD5,795)▷ お問い合わせ
  Site Licence (同一拠点内共用可)¥958,655 (USD8,795)▷ お問い合わせ
  Enterprise wide(複数拠点共用可)¥1,285,655 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本調査レポートは、世界のジストロフィー表皮水疱症治療市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療タイプ別(抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他)分析、疾患別分析、流通チャンネル別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)分析、競争状況などを掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界のジストロフィー表皮水疱症治療市場規模:治療タイプ別(抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他)
・世界のジストロフィー表皮水疱症治療市場規模:疾患別
・世界のジストロフィー表皮水疱症治療市場規模:流通チャンネル別
・世界のジストロフィー表皮水疱症治療市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)
・競争状況

Dystrophic Epidermolysis Bullosa Treatment Market – Scope of the Report

TMR’s report on the global dystrophic epidermolysis bullosa treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global dystrophic epidermolysis bullosa treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global dystrophic epidermolysis bullosa treatment market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global dystrophic epidermolysis bullosa treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global dystrophic epidermolysis bullosa treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global dystrophic epidermolysis bullosa treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global dystrophic epidermolysis bullosa treatment market.

The report delves into the competition landscape of the global dystrophic epidermolysis bullosa treatment market. Key players operating in the global dystrophic epidermolysis bullosa treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global dystrophic epidermolysis bullosa treatment market that have been profiled in this report.

Key Questions Answered in Dystrophic Epidermolysis Bullosa Treatment Market Report

What is the scope of growth of companies present in the global dystrophic epidermolysis bullosa treatment market?
What will be the Y-o-Y growth of the global dystrophic epidermolysis bullosa treatment market between 2020 and 2030?
What is the influence of changing trends in technologies on the global dystrophic epidermolysis bullosa treatment market?
Will North America continue to be the most profitable market for dystrophic epidermolysis bullosa treatment providers?
Which factors are anticipated to hamper the growth of the global dystrophic epidermolysis bullosa treatment market during the forecast period?
Which are the leading companies in the global dystrophic epidermolysis bullosa treatment market?
Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global dystrophic epidermolysis bullosa treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global dystrophic epidermolysis bullosa treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the dystrophic epidermolysis bullosa treatment market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the dystrophic epidermolysis bullosa treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global dystrophic epidermolysis bullosa treatment market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global dystrophic epidermolysis bullosa treatment market more reliably and accurately.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dystrophic Epidermolysis Bullosa Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Dystrophic Epidermolysis Bullosa Treatment Market Introduction

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, 2018–2030

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Novel Therapies for Dystrophic Epidermolysis Bullosa Treatment

5.2. Pipeline Analysis

5.3. Potential Market of Phase 3 Pipeline Drug Therapies for Dystrophic Epidermolysis Bullosa

5.4. Epidemiology of Dystrophic Epidermolysis Bullosa

5.5. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Treatment Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Treatment Type, 2018–2030

6.3.1. Antibiotics

6.3.2. Corticosteroids

6.3.3. Opioid Analgesics

6.3.4. Anticonvulsant

6.3.5. Others

6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Disease Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Disease Type, 2018–2030

7.3.1. Dominant Dystrophic Epidermolysis Bullosa

7.3.2. Recessive Dystrophic Epidermolysis Bullosa

7.4. Market Attractiveness Analysis, by Disease Type

8. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Distribution Channel, 2018–2030

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Market Value Forecast by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Market Attractiveness Analysis, by Country/Region

10. North America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Treatment Type, 2018–2030

10.2.1. Antibiotics

10.2.2. Corticosteroids

10.2.3. Opioid Analgesics

10.2.4. Anticonvulsant

10.2.5. Others

10.3. Market Value Forecast, by Disease Type, 2018–2030

10.3.1. Dominant Dystrophic Epidermolysis Bullosa

10.3.2. Recessive Dystrophic Epidermolysis Bullosa

10.4. Market Value Forecast, by Distribution Channel, 2018–2030

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Others

10.5. Market Value Forecast, by Country, 2018–2030

10.5.1. U.S.

10.5.2. Canada

10.6. Market Attractiveness Analysis

10.6.1. By Treatment Type

10.6.2. By Disease Type

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

11.1.Introduction

11.1.1. Key Findings

11.2.Market Value Forecast, by Treatment Type, 2018–2030

11.2.1. Antibiotics

11.2.2. Corticosteroids

11.2.3. Opioid Analgesics

11.2.4. Anticonvulsant

11.2.5. Others

11.3.Market Value Forecast, by Disease Type, 2018–2030

11.3.1. Dominant Dystrophic Epidermolysis Bullosa

11.3.2. Recessive Dystrophic Epidermolysis Bullosa

11.4.Market Value Forecast, by Distribution Channel, 2018–2030

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Others

11.5.Market Value Forecast, by Country/Sub-region, 2018–2030

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6.Market Attractiveness Analysis

11.6.1. By Treatment Type

11.6.2. By Disease Type

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

12.1.Introduction

12.1.1. Key Findings

12.2.Market Value Forecast, by Treatment Type, 2018–2030

12.2.1. Antibiotics

12.2.2. Corticosteroids

12.2.3. Opioid Analgesics

12.2.4. Anticonvulsant

12.2.5. Others

12.3.Market Value Forecast, by Disease Type, 2018–2030

12.3.1. Dominant Dystrophic Epidermolysis Bullosa

12.3.2. Recessive Dystrophic Epidermolysis Bullosa

12.4.Market Value Forecast, by Distribution Channel, 2018–2030

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Others

12.5.Market Value Forecast, by Country/Sub-region, 2018–2030

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6.Market Attractiveness Analysis

12.6.1. By Treatment Type

12.6.2. By Disease Type

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

13.1.Introduction

13.1.1. Key Findings

13.2.Market Value Forecast, by Treatment Type, 2018–2030

13.2.1. Antibiotics

13.2.2. Corticosteroids

13.2.3. Opioid Analgesics

13.2.4. Anticonvulsant

13.2.5. Others

13.3.Market Value Forecast, by Disease Type, 2018–2030

13.3.1. Dominant Dystrophic Epidermolysis Bullosa

13.3.2. Recessive Dystrophic Epidermolysis Bullosa

13.4.Market Value Forecast, by Distribution Channel, 2018–2030

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Others

13.5.Market Value Forecast, by Country/Sub-region, 2018–2030

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6.Market Attractiveness Analysis

13.6.1. By Treatment Type

13.6.2. By Disease Type

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

14.1.Introduction

14.1.1. Key Findings

14.2.Market Value Forecast, by Treatment Type, 2018–2030

14.2.1. Antibiotics

14.2.2. Corticosteroids

14.2.3. Opioid Analgesics

14.2.4. Anticonvulsant

14.2.5. Others

14.3.Market Value Forecast, by Disease Type, 2018–2030

14.3.1. Dominant Dystrophic Epidermolysis Bullosa

14.3.2. Recessive Dystrophic Epidermolysis Bullosa

14.4.Market Value Forecast, by Distribution Channel, 2018–2030

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Others

14.5.Market Value Forecast, by Country/Sub-region, 2018–2030

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6.Market Attractiveness Analysis

14.6.1. By Treatment Type

14.6.2. By Disease Type

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competitive Landscape

15.1. Company Profiles

15.1.1. Krystal Biotech

15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.1.2. Growth Strategies

15.1.1.3. SWOT Analysis

15.1.2. Castle Creek Biosciences, Inc.

15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.2.2. Growth Strategies

15.1.2.3. SWOT Analysis

15.1.3. Abeona Therapeutics, Inc.

15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.3.2. Growth Strategies

15.1.3.3. SWOT Analysis

15.1.4. Amryt Pharma plc

15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.4.2. Growth Strategies

15.1.4.3. SWOT Analysis

15.1.5. Wings Therapeutics

15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.5.2. Growth Strategies

15.1.5.3. SWOT Analysis

15.1.6. Phoenix Tissue Repair

15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.6.2. Growth Strategies

15.1.6.3. SWOT Analysis

15.1.7. InMed Pharmaceuticals, Inc.

15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.7.2. Growth Strategies

15.1.7.3. SWOT Analysis

15.1.8. RegeneRx

15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.8.2. Growth Strategies

15.1.8.3. SWOT Analysis

15.1.9. Holostem Terapie Avanzate S.r.l.

15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.1.9.2. Growth Strategies

15.1.9.3. SWOT Analysis

List of Tables

Table 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2030

Table 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 05: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 06: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 07: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 08: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 09: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 10: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 11: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 12: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030

Table 13: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 15: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 16: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 17: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 18: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 19: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 20: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030

Table 21: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 22: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 23: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 24: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030